Literature DB >> 24302556

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.

Florian Malchers1, Felix Dietlein, Jakob Schöttle, Xin Lu, Lucia Nogova, Kerstin Albus, Lynnette Fernandez-Cuesta, Johannes M Heuckmann, Oliver Gautschi, Joachim Diebold, Dennis Plenker, Masyar Gardizi, Matthias Scheffler, Marc Bos, Danila Seidel, Frauke Leenders, André Richters, Martin Peifer, Alexandra Florin, Prathama S Mainkar, Nagaraju Karre, Srivari Chandrasekhar, Julie George, Steffi Silling, Daniel Rauh, Thomas Zander, Roland T Ullrich, H Christian Reinhardt, Francois Ringeisen, Reinhard Büttner, Lukas C Heukamp, Jürgen Wolf, Roman K Thomas.   

Abstract

UNLABELLED: The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified tumors are also sensitive to fibroblast growth factor receptor (FGFR) inhibition. We found that, in contrast with other recurrent amplifications, the 8p12 region included multiple centers of amplification, suggesting marked genomic heterogeneity. FGFR1-amplified tumor cells were dependent on FGFR ligands in vitro and in vivo. Furthermore, ectopic expression of FGFR1 was oncogenic, which was enhanced by expression of MYC. We found that MYC was coexpressed in 40% of FGFR1-amplified tumors. Tumor cells coexpressing MYC were more sensitive to FGFR inhibition, suggesting that patients with FGFR1-amplified and MYC-overexpressing tumors may benefit from FGFR inhibitor therapy. Thus, both cell-autonomous and non-cell-autonomous mechanisms of transformation modulate FGFR dependency in FGFR1-amplified lung cancer, which may have implications for patient selection for treatment with FGFR inhibitors. SIGNIFICANCE: Amplification of FGFR1 is one of the most frequent candidate targets in lung cancer. Here, we show that multiple factors affect the tumorigenic potential of FGFR1, thus providing clinical hypotheses for refinement of patient selection. 2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24302556     DOI: 10.1158/2159-8290.CD-13-0323

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  45 in total

Review 1.  [Cytological material for molecular pathology].

Authors:  L C Heukamp; L Bubendorf
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

2.  FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.

Authors:  Kaixuan Wang; Wenxiang Ji; Yongfeng Yu; Ziming Li; Xiaomin Niu; Weiliang Xia; Shun Lu
Journal:  Oncogene       Date:  2018-06-01       Impact factor: 9.867

3.  A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.

Authors:  Paul K Paik; Ronglai Shen; Michael F Berger; David Ferry; Jean-Charles Soria; Alastair Mathewson; Claire Rooney; Neil R Smith; Marie Cullberg; Elaine Kilgour; Donal Landers; Paul Frewer; Nigel Brooks; Fabrice André
Journal:  Clin Cancer Res       Date:  2017-06-14       Impact factor: 12.531

Review 4.  Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Authors:  David R Gandara; Peter S Hammerman; Martin L Sos; Primo N Lara; Fred R Hirsch
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

5.  MYCxing it up with FGFR1 in squamous cell lung cancer.

Authors:  William Lockwood; Katerina Politi
Journal:  Cancer Discov       Date:  2014-02       Impact factor: 39.397

Review 6.  Current concepts on the molecular pathology of non-small cell lung carcinoma.

Authors:  Junya Fujimoto; Ignacio I Wistuba
Journal:  Semin Diagn Pathol       Date:  2014-06-12       Impact factor: 3.464

7.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Authors:  Lucia Nogova; Lecia V Sequist; Jose Manuel Perez Garcia; Fabrice Andre; Jean-Pierre Delord; Manuel Hidalgo; Jan H M Schellens; Philippe A Cassier; D Ross Camidge; Martin Schuler; Ulka Vaishampayan; Howard Burris; G Gary Tian; Mario Campone; Zev A Wainberg; Wan-Teck Lim; Patricia LoRusso; Geoffrey I Shapiro; Katie Parker; Xueying Chen; Somesh Choudhury; Francois Ringeisen; Diana Graus-Porta; Dale Porter; Randi Isaacs; Reinhard Buettner; Jürgen Wolf
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

Review 8.  Emerging biomarkers in head and neck cancer in the era of genomics.

Authors:  Hyunseok Kang; Ana Kiess; Christine H Chung
Journal:  Nat Rev Clin Oncol       Date:  2014-11-18       Impact factor: 66.675

9.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

10.  FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Authors:  Murry W Wynes; Trista K Hinz; Dexiang Gao; Michael Martini; Lindsay A Marek; Kathryn E Ware; Michael G Edwards; Diana Böhm; Sven Perner; Barbara A Helfrich; Rafal Dziadziuszko; Jacek Jassem; Szymon Wojtylak; Aleksandra Sejda; Joseph M Gozgit; Paul A Bunn; D Ross Camidge; Aik-Choon Tan; Fred R Hirsch; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.